The IRA is significantly impacting the commercial landscape for prescription drugs, including drug development. Two of the most significant developments of the IRA include the Medicare drug price negotiation and the Medicare Part D redesign.

Points of discussion will include:

• Analyzing the impact of IRA reforms on the biopharmaceutical industry
• Review of first 10 drugs chose for negotiation process and why?
  • What will the criteria for the next group of drugs be?
• How does this play into the anticipated 2025 redesign for Part D
  • How would a new Administration in 2024 affect the redesign plan?